Primary central nervous system lymphoma (PCNSL) is a rare and aggressive lymphoma with a dismal outcome in the majority of cases. In clinical practice, prognosis is estimated through clinical risk scoring, which can help in guiding the appropriate management. However, there is no established biomarker to track treatment response and relapse. Here, we showed that tumor expression of activated STAT6 (pSTAT6) correlates with cerebral spinal fluid (CSF) levels of its activator interleukins, IL-4 (r 0.62, p=0.013) and IL-10 (r 0.97, p= <0.001), suggesting their potential use as surrogate biomarkers of JAK/STAT activation. Elevated CSF cytokines levels were significantly associated with a shorter progression free survival (IL-4 HR 2.02, 95% CI 1.07-2.99; IL-10 HR 3.32, 95%CI 1.18-1.84), and presented a positive trend with inferior overall survival (IL-4 HR 1.75, 95% CI 0.93-2.45; IL-10 HR 2.09, 95%CI 0.89-1.43). In addition, CSF IL-4 and IL-6 levels correlated with response to therapy and relapsed disease. These results indicate that the CSF levels of IL-4 and IL-10 may be useful biomarkers of prognosis and disease activity in patients with PCNSL.

STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma

Mondello P.
Primo
;
Cuzzocrea S.
Secondo
;
Pitini V.;
2020-01-01

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare and aggressive lymphoma with a dismal outcome in the majority of cases. In clinical practice, prognosis is estimated through clinical risk scoring, which can help in guiding the appropriate management. However, there is no established biomarker to track treatment response and relapse. Here, we showed that tumor expression of activated STAT6 (pSTAT6) correlates with cerebral spinal fluid (CSF) levels of its activator interleukins, IL-4 (r 0.62, p=0.013) and IL-10 (r 0.97, p= <0.001), suggesting their potential use as surrogate biomarkers of JAK/STAT activation. Elevated CSF cytokines levels were significantly associated with a shorter progression free survival (IL-4 HR 2.02, 95% CI 1.07-2.99; IL-10 HR 3.32, 95%CI 1.18-1.84), and presented a positive trend with inferior overall survival (IL-4 HR 1.75, 95% CI 0.93-2.45; IL-10 HR 2.09, 95%CI 0.89-1.43). In addition, CSF IL-4 and IL-6 levels correlated with response to therapy and relapsed disease. These results indicate that the CSF levels of IL-4 and IL-10 may be useful biomarkers of prognosis and disease activity in patients with PCNSL.
2020
File in questo prodotto:
File Dimensione Formato  
stat6 in PCNSL.pdf

Open Access dal 01/03/2021

Descrizione: Accepted article
Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Copyright dell'editore
Dimensione 565.84 kB
Formato Adobe PDF
565.84 kB Adobe PDF Visualizza/Apri
3165671.pdf

solo utenti autorizzati

Descrizione: Articolo principale
Tipologia: Versione Editoriale (PDF)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 4 MB
Formato Adobe PDF
4 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/3165671
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 10
social impact